Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by vikingguyon May 22, 2017 2:00pm
186 Views
Post# 26270627

RE:Corrected timing of FDA acceptance of Ibalizumab application

RE:Corrected timing of FDA acceptance of Ibalizumab applicationGreat post SPCEO and nice to read on a day when the market is closed in Canada. One small correction to your post would be when the FDA issues priority review and a pdufa date, it will be 6 months from the filing date of the BLA and not the acceptance. Although Mackie and some other analysts are giving early 2018 for approval now I dont think that will be the case unless we are delayed. We should get our PDUFA for early Nov. and then we can easily get an early approval from that date.

If everything goes well we should get BLA acceptance, a PDUFA and priority review sometime in mid June and from what I've read (although not official) once a breakthrough therapy revieves a PDUFA, it is extremely rare for the drug not to be approved on or before that date. Anybody following the Thera story will want to be fully invested when we recieve acceptance in my opionion, institutions and deep pocket investors could be waiting for a PDUFA.
Bullboard Posts